Tracking the Development of Novel Drugs in Glioma

home / publications / supplements / tracking-the-development-of-novel-drugs-in-glioma
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center

Dr Umemura on the Development of ONC201 in H3K27M-Mutant Diffuse Midline Glioma

Yoshie Umemura, MD
June 12th 2024
Video

Yoshie Umemura, MD, discusses the development of ONC201 in patients with H3K27M-mutated diffuse midline glioma.

Stephen Bagley, MD, MSCE, assistant professor, medicine, hematology-oncology, the Hospital of the University of Pennsylvania; section chief, Neuro-Oncology, assistant professor, medicine, neurosurgery, Penn Medicine

Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas

Stephen Bagley, MD, MSCE
March 21st 2024
Podcast

Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.

Stephen Bagley, MD, MSCE, assistant professor, medicine, section chief, Neuro-Oncology, the Hospital of the University of Pennsylvania, Abramson Cancer Center

ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Mutated Diffuse Midline Gliomas

Megan Hollasch
February 14th 2024
Article

The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.

Stephen Bagley, MD, MSCE

Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas

Stephen Bagley, MD, MSCE
January 24th 2024
Video

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.

Ashley Sumrall, MD, FACP

Investigational Targeted Therapies Broaden Glioma Research Efforts and Define Disease Subsets

Ashling Wahner
January 15th 2024
Article

Ashley Sumrall, MD, FACP, discusses ongoing research with the DRD2 dopamine receptor–targeted agent ONC201 in patients with H3K27M-mutated glioma.

Ashley Sumrall, MD, FACP

Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline Gliomas

Ashley Sumrall, MD
January 8th 2024
Video

Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.